Dr. K. R. Gopi

• MBBS – Madras Medical College / Madras University, Chennai, India (1987)
• MD in Internal Medicine – Kilpauk Medical College / The Tamil Nadu Dr. M.G.R. Medical University, Chennai, India (1992)
• DNB in Medical Oncology – National Board of Examinations, New Delhi, India (2013)

• Fellowship in Medical Oncology – Royal College of Physicians (RCP), UK
• Extensive Oncology and Palliative Care Training – Various leading NHS cancer centers, United Kingdom (1995–2011)

• MRCP – Royal College of Physicians of Ireland
• European Board Certification in Medical Oncology

• Breast Cancer
• Colorectal Cancer
• Ovarian and Prostate Cancers
• Lymphomas and Leukemias
• Hepato-Biliary-Pancreatic Cancers
• Post-transplant Lymphoproliferative Disorders
• Cancers in the Frail and Elderly

• Advanced Chemotherapy and Targeted Therapy Administration
• Subcutaneous Morphine Infusion for Pain Management
• Palliative Care for Terminally Ill Patients
• Individualized Treatment Planning for Complex Malignancies

Senior Consultant Medical Oncologist, Dr. Rela Institute & Medical Centre, Chennai

Senior Consultant Medical Oncologist, Gleneagles Global Hospital, Chennai

Senior Consultant Medical Oncologist, Apollo Speciality Hospital, Chennai

• Consultant Medical Oncologist & Senior Registrar, NHS Hospitals, United Kingdom (1995–2011) – Served at Peterborough NHS, South Manchester University Hospital NHS, Christie NHS Manchester, Clatterbridge NHS Liverpool, Western General Hospital Edinburgh, and Leeds Teaching Hospitals NHS
• Consultant Physician, India (1987–1995)

• Menon, J., Vij, M., Hakeem, A. R., Gopi, K. R., Bibi, A., Shanmugam, N., Reddy, M. S., & Rela, M. (2021). Late-Onset Peripheral T-Cell Lymphoma Not Otherwise Specified in a Liver Transplant Recipient: A Rare Subtype of Posttransplant Lymphoproliferative Disorder. Journal of Clinical and Experimental Hepatology, 11(4), 518-521.
• Gopi, K. R. (Investigator). (1995–2011). Contributed to multiple landmark international clinical trials in the UK, including the Letrozole trial in breast cancer, Sunitinib trial in soft tissue sarcoma, Imatinib trial in chronic myeloid leukaemia, Trastuzumab HERA trial, and Bevacizumab trials in metastatic ovarian and colorectal cancers.

• Pioneered the introduction of subcutaneous morphine infusion in India for terminally ill cancer patients, significantly advancing palliative care standards.
• Key Investigator in major UK Clinical Trials shaping modern oncology practices (Letrozole, Sunitinib, Imatinib, Trastuzumab HERA, Bevacizumab, Panitumumab, Rituximab).
• Recognized for over three decades of excellence in Medical Oncology and Palliative Care across the United Kingdom and India.

• What is the role of targeted therapy in treating breast and colorectal cancers? Targeted therapy involves drugs designed to specifically attack cancer cells without harming normal cells, based on the tumor's genetic makeup. In breast cancer, therapies like Trastuzumab target HER2-positive cells, significantly improving survival rates. For colorectal cancer, medications such as Bevacizumab or Panitumumab target specific pathways (like VEGF or EGFR) that tumors use to grow and spread. These therapies are often combined with traditional chemotherapy to enhance efficacy and reduce the likelihood of recurrence.
• How are post-transplant lymphoproliferative disorders (PTLD) managed? PTLD is a rare but serious complication following solid organ transplantation, often linked to the Epstein-Barr virus (EBV) and the immunosuppressive drugs required to prevent organ rejection. Management typically begins with a careful reduction of immunosuppressive therapy to allow the patient's immune system to fight the abnormal lymphocytes. If this is insufficient, targeted therapies like Rituximab (an anti-CD20 monoclonal antibody) or customized chemotherapy regimens are employed. The goal is to eradicate the lymphoma while preserving the function of the transplanted organ.
• What is subcutaneous morphine infusion, and how does it help in palliative care? Subcutaneous morphine infusion is a highly effective method of pain management for terminally ill patients who can no longer take oral medications due to severe nausea, swallowing difficulties, or bowel obstruction. It involves delivering a continuous, controlled dose of morphine through a small needle placed just under the skin, usually via a portable syringe driver. This ensures steady pain relief without the peaks and troughs associated with intermittent dosing, significantly improving the patient's comfort and overall quality of life during advanced stages of cancer.
• How is cancer treatment adapted for elderly or frail patients? Treating cancer in the elderly or frail requires a highly individualized approach, balancing the efficacy of the treatment against potential toxicities. A comprehensive geriatric assessment is often performed to evaluate the patient's overall health, comorbidities, cognitive function, and nutritional status. Based on this, oncologists may adjust chemotherapy dosages, opt for less toxic targeted therapies or hormonal treatments, and place a strong emphasis on supportive and palliative care. The primary objective is to control the disease while maintaining independence and maximizing the patient's quality of life.